|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | 女性急性心肌梗塞的临床特点显示文摘目的为了解女性急性心肌梗塞(AMI)的临床特点,以提高防治效果。方法对北京地区防治冠心病协作组1990~1991年连续收治的1614例患者(男1185,女429),进行男女比较分析。根据患者年龄分为(<45,45~54,55~64,≥65岁)四组,比较患者例数、并发症及病死率。结果四组男与女患者比例分别为17.8:1,6.1:1,3.2:1和1.8:1。女性并发心源性休克者明显多于男性。发病4周病死率,女性14.7%明显高于男性9.4%。在45~54岁组内,差异亦有显著性(1.2%比0.7%)。结论提示与年龄有关的雌激素水平变化对女性AMI临床特点有明显的影响。 | Beijing Collaborative Study Group of Coronary Heart Disease 100700 (correspondewce: Beijing General Hospital, PLA, Beijing 100700) | 1998 | 中华心血管病杂志1998，26，3： | 47 |
| 2 | 常见先天性心脏病介入治疗中国专家共识 五、先天性心脏病复合畸形的介入治疗显示文摘先天性心脏复合畸形为同时患有2种或2种以上心血管畸形,能够同期进行介入治疗,其技术操作并非单一技术的简单相加,而有其特殊性。本文介绍室间隔缺损合并房间隔缺损、动脉导管未闭、肺动脉瓣狭窄;房间隔缺损合并动脉导管未闭、肺动脉瓣狭窄、左房室瓣狭窄(鲁登巴赫综合征)及主动脉缩窄合并动脉导管未闭等复合畸形的病理生理改变与临床特点、介入治疗适应证和禁忌证、治疗原则和注意事项、术后处理以及疗效判定等。 | Committee on Congenital Heart Diseases,Internal Medicine Branch of Cadiovascular Diseases,Chinese Physicians’ Association | 2011 | 介入放射学杂志2011，20，5： | 26 |
| 3 | A prospective randomized antiplatelet trial of cilostazol versus clopidogrel in patients with bare metal stent显示文摘Background Cilostazol is a newly developed antiplatelet drug that has been widely applied for clinical use. Its antiplatelet action appears to be mainly related to inhibition of intracellular phosphodiesterase activity. Recently, cilostazol has been used for antiplatelet therapy after coronary bare metal stent implantation for thrombosis and restenosis prevention. This prospective randomized and double blind trial was designed to investigate the safety and efficacy of cilostazol for the prevention of late restenosis and acute or subacute stent thrombosis. Methods One hundred and twenty patients who underwent elective stent were randomly assigned to treatment group with cilostazol 200 mg/d (n = 60), clopidogrel 75 mg/d and aspirin 100 mg/d or to control group with clopidogrel treatment 75 mg/d (n = 60) and aspirin 100 mg/d. Follow-up coronary angiography was performed 6-9 months later. Results Nine months major adverse cardio-cerebral event (MACCE) were lower in treatment groups (P<0.05). The quantitative coronary angiography (QCA) at 6 months follow-up showed that minimum lumen diameter (MLD) was higher in treatment group than that of control group [(2.14±0.52)mm vs (1.82±0.36)mm, P<0.05]. Late lumen loss (LL) [(0.82±0.42)mm vs (1.31±0.58)mm; P<0.01], restenosis rate (RR) (14% vs 32%; P<0.05) and target lesion revascularizaion (TLR) rate (5% vs 17%; P<0.05) were lower in treatment group than in control group. Conclusion Cilostazol therapy is an effective regimen for prevention not only stent thrombosis but also RR and TLR through reducing MLD without the risk of increasing bleeding. | CHEN Yun-dai, LU Yan-ling, JIN Ze-ning, YUAN Fei and Lü Shu-zhengDepartment of Cardiology, Beijing Anzhen Hospital, Capital University of Medical Sciences Beijing Institute of Heart, Lung and Blood Vessel, Beijing 100029, China | 2006 | Chinese Medical Journal2006，，5： | 15 |
| 4 | Methodological study on real-time three-dimensional echo-cardiography and its application in the diagnosis of complex congenital heart disease显示文摘背景实时三维的回响心动描记法(RT-3DE ) 在过去几年期间使心脏的成像的改进革命化。然而,到目前为止为 RT-3DE 没有标准考试方法。这研究试图建立 RT-3DE 的诊断方法并且在复杂的先天的心疾病(CHD ) 的诊断评估它的申请。有复杂 CHD 的五十个病人被 RT-3DE 与实时 3DE 和 FullVolume 的模式检查的方法。一系列新奇容量的看法与凡·普拉格结合了顺序的部分途径被介绍揭示心的病理学的形态学,它与二维的回响心动描记法(2DE ) 的调查结果相比, angiography 和心脏的外科。在 50patients 的结果,完整的体积的 190 图象获得在几声学的窗口 includingsubcostal 被执行,顶端并且同等不连胸骨的区域。在他们之中,(179/190 )94.2% 图象获得是成功的。最部分的容量的看法能清楚地在 92.6% 成功的图象获得被显示。然而,部分容量的看法不能清楚地在 7.4% 被显示,它主要由于考试地点,不适当的 instrumentmulti 参数背景和在完整的 Volumeacquisitions 捕获的整个心的不够的信息的差的观点条件。作为与外科的调查结果和 angiography 相比, RT-3DE 与单个中庭与大动脉和其它的改正的调换包括 1 在 2 种情况中做了修正到 diagnoses 并且僧帽形劈开。2DE 开始为这 2 个病人做的 diagnoses 是有大动脉和 completeatrio 室的氏族的缺点的调换的两倍插头权利室。结论 RT-3DE 能清楚地由容量的看法通过提供更空间的增进知识的心血管的结构与顺序的部分途径相结合的一系列小说显示复杂 CHD 的病理学的形态学,它为 RT-3DE 诊断提供一个实际方法。 | CHEN Guo-zhen, HUANG Guo-ying, LIANG Xue-cun, MA Xiao-jing, CHEN Wei-da, TAO Zi-yu and LIN Qi-shan Pediatric Heart Center, Children’s Hospital of Fudan University Department of Pediatrics, Shanghai Medical College, Shanghai 200032, China | 2006 | Chinese Medical Journal2006，，14： | 9 |
| 5 | Comparative study of on-pump and off-pump coronary bypass surgery for patients with triple coronary artery disease显示文摘Objective To compare the clinical results of on-pump and off-pump coronary bypass surgery in patients with triple-vessel disease. Methods A total of 300 consecutive isolated multiple CABG patients entered into off-pump coronary artery bypass (OPCAB group, n=150) or CABG with cardiopulmonary bypass (CPB) (CCABG group, n=150). There were no significant difference regarding the degree of angina, history of myocardial infarction, diabetes and left main disease between two groups. The ejection fraction in OPCAB before surgery was lower than CCABG (P<0.01). More patients had a history of stroke, and abnormal renal function in OPCAB pre-operatively( P< 0.01 ). Single deep pericardial stay suture with a sling snared down was used to expose the target vessels in OPCAB, along with a stabilizer and a coronary shunt. Medi-Stim Butterfly Flowmeter was used to measure the flow of grafts in both groups. Results No one in OPCAB needed to convert to CCABG. The number of the distal anastomosis and the index of completeness of revisualization (ICR) were similar in both groups. The respiratory support time, the volume of chest tube drainage and blood transfusion were less in OPCAB than in CCABG post-operatively (both P<0.01). The incidence of pulmonary dysfunction and renal insufficiency were less in OPCAB than in CCABG post-operatively ( both P<0.05 ) . There was no significant difference in the mortality and other morbidities (peri-opetative MI, stroke, atrial fibrillation). Conclusion OPCAB can be applied to patients with triple vessels disease and achieved similar completeness of revascularization, similar early surgical results with shorter respiratory support, reduced transfusion requirement, less pulmonary dysfunction and abnormal renal function. | CHEN Xin, XU Ming, SHI Hong-wei, MU Xin-wei, CHEN Zhen-qiang, QIU Zhi-bing Nanjing First Hospital Affiliated to Nanjing Medical University, Nanjing Heart Institute, Nanjing, 210006 P.R.China | 2004 | 介入放射学杂志2004，13，S2： | 7 |
| 6 | MicroRNA: A matter of life or death显示文摘Progressive cell loss due to apoptosis is a pathological hallmark implicated in a wide spectrum of degenerative diseases such as heart disease, atherosclerotic arteries and hypertensive vessels, Alzheimer's disease and other neurodegenerative disorders. Tremendous efforts have been made to improve our understanding of the molecular mechanisms and signaling pathways involved in apoptosistic cell death. Once ignored completely or overlooked as cellular detritus, microRNAs (miRNAs) that were discovered only a decade ago, have recently taken many by surprise. The importance of miRNAs has steadily gained appreciation and miRNA biology has exploded into a massive swell of interest with enormous range and potential in almost every biological discipline because of their widespread expression and diverse functions in both animals and humans. It has been established that miRNAs are critical regulators of apoptosis of various cell types. These small molecules act by repressing the expression of either the proapoptotic or antiapoptotic genes to produce antiapoptotic or proapoptotic effects. Appealing evidence has been accumulating for the involvement of miRNAs in human diseases associated with apoptotic cell death and the potential of miRNAs as novel therapeutic targets for the treatment of the diseases. This editorial aims to convey this message and to boost up the research interest by providing a timely, comprehensive overview on regulation of apoptosis bymiRNAs and a synopsis on the pathophysiologic implications of this novel regulatory network based on the currently available data in the literature. It begins with a brief introduction to apoptosis and miRNAs, followed by the description of the fundamental aspects of miRNA biogenesis and action, and the role of miRNAs in regulating apoptosis of cancer cells and cardiovascular cells. Speculations on the development of miRNAs as potential therapeutic targets are also presented. Remarks are also provided to point out the unanswered questions and to outline the new directions for the future research of the field. | Zhiguo Wang, Research Center, Montreal Heart Institute and Department of Medicine, University of Montreal, Montreal, PQ H1T 1C8, Canada | 2010 | World Journal of Biological Chemistry2010，1，4： | 6 |
| 7 | Report of the Joint International Society and Federation of Cardiology/World Health Organization Task Force on Standardization of Clinical Nomenclature 显示文摘 | Nomenclature and criteria for diagnosis of ischemic heart disease | 1979 | Circulation1979，59，： | 2 |
| 8 | MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals:a randomised placebo-controlled trial显示文摘 | Heart Protection Study Collaborative Group | | The Lancet0，，： | 2 |
| 9 | Wg signaling in Drosophila heart development as a pioneering model显示文摘The heart is one of the first functional embryonic organs occurring during development. The fundamental developmental processes and genes involved in cardiogenesis are conserved between the invertebrates and vertebrates. In the past fifteen years, one of signaling pathways that has been best characterized in heart development in both invertebrates and vertebrates is the Wg/Wnt signaling pathways. Since our discovery of the Wg signaling required for the early heart development in Drosophila, the past fifteen years have witnessed tremendous progress in the understanding of specific Wnt signaling pathways in vertebrate cardiogenesis. This review will summarize the current state of knowledge of Wg signaling transduction in Drosophila heart development, which will benefit our understanding of vertebrate cardiogenesis and human congenital malformations. | Xiushan Wu The Center for Heart Development, Key Lab of MOE for Developmental Biology and Protein Chemistry, College of Life Sciences, Hunan Normal University, Changsha, 410081, China | 2010 | Journal of Genetics and Genomics2010，37，9： | 2 |
| 10 | C-reactive protein concentration and the vascular benefits of statin therapy: an analysis of 20 536 patients in the Heart Protection Study显示文摘 | Heart Protection Study Collaborative Group | 2011 | The Lancet . 2011 (9764)2011，，： | 2 |
| 11 | Prograte turbulence following s in patient s with idiopathic dilated cardiomyopathy显示文摘 | GRIMM W SCHMIDT G nostic significance of heart vent rieular premature beat MAISCH B | 2003 | J Cardiovasc Electrophysiol2003，14，： | 1 |
| 12 | The effect of carvedilol on morbidity and mortality in patients with chronic heart failure 显示文摘 | | 1996 | N Engl J Med1996，334，21： | 1 |
| 13 | 2005 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care显示文摘 | ECC Committee Subcommittees and Task Forces of the American Heart Association | 2005 | Circulation2005，112，24： | 1 |
| 14 | MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals:a randomised placebocontrolled trial显示文摘 | Heart Protection Study Investigators | 2002 | Lancet2002，360，9326： | 1 |
| 15 | The SOLVD Investiga- tors显示文摘 | Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure | 1991 | N Engl J Med1991，325，： | 1 |
| 16 | Guidelines for the evaluation and manage- mant of chronic heart failure in the adult显示文摘 | American Heart Association | 2001 | Circulation2001，104，24： | 1 |
| 17 | Update on the 1987 task force report on high blood pressure in children and adolescents:A working group report from the national high blood pressure education program 显示文摘 | National heart lung and blood institute | 1996 | Pediatrics1996，98，4： | 1 |
| 18 | A reporting system on patients evaluated for coronary artery disease 显示文摘 | American Heart Association Committee Report | 1975 | Circulation1975，51，： | 1 |
| 19 | Diuretic versus alpha-blocker as first-step antihypertensive therapy:final resuits from the Antihypertesive and Lipid-lowering Treatment to Prevent Heart Attack Trial(ALLHAT)显示文摘 | Antihypertensive and Lipid-lowering Treatment to Prevent Heart Attack Trial Collaborative Research Group | 2003 | Hypertension2003，42，： | 1 |
| 20 | 2005 American Heart Association Guidelines for cardiopulmonary resuscitation and emergency cardiovascular care 显示文摘 | ECC Committee Subcommittees and Task Forces of the American Heart Association | 2005 | Circulation2005，112，24： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员